IMS's Incivek reporting hitch spurs stock swing

IMS Health continues to assess a data-supply glitch that led to an underreporting of ­prescriptions for Vertex Pharmaceuticals' hepatitis C drug Incivek.

During the period in question—the last two weeks of September—IMS data showed relatively flat TRx of the drug. Various financial analysts interpreted the dip as a sign that usage of the new drug had peaked.

Instead, IMS said, a key supplier had missed some mail order prescriptions. IMS adjusted for the issue but due to the short duration is not restating the history, a spokseman for the company said.

But when the company initially disclosed the hitch, Vertex shares jumped 7% as investors expected that a new sales report would reflect more comprehensive estimates. Then, when new IMS data still did not show sales had risen, shares declined by more than 6%.

As of early October, Incivek scripts continued to climb. Vertex is battling Merck's Victrelis for hep-C market share.

Because of IMS's script-reporting issues, rival Rx tracker Wolters Kluwer said it verified the quality of data it received from vendors for Incivek and Victrelis, saying it had not experienced a significant loss of data and continued to receive “a consistent data flow.”

A Vertex spokesperson said the firm doesn't comment on IMS data.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.